Keywords: Eisai, Halaven, Pfizer, Bristol-Myers, Eliquis, Johnson & Johnson, Rilpivirine, Edurant, Eviplera, Gilead, Germany, AMNOG, IQWiG, G-BA

Germany's G-BA backs Eisai's Halaven; IQWiG finds some added benefit for Eliquis and rilpivirine

Article | 23 April 2012

Print This

The German Federal Joint Committee (G-BA), the supreme decision-making body of the self-governing medical system in Germany, says that it ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in